Incomplete Freund's adjuvant
- Generic Name
- Incomplete Freund's adjuvant
- Drug Type
- Biotech
- Unique Ingredient Identifier
- Y9DQK7DB5U
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
Phase 2
Completed
- Conditions
- Iris MelanomaStage IIC MelanomaStage IV MelanomaExtraocular Extension MelanomaStage IIIC MelanomaCiliary Body and Choroid Melanoma, Medium/Large SizeStage IIB MelanomaStage IIIA MelanomaStage IIIB Melanoma
- Interventions
- Biological: tyrosinase peptideBiological: gp100 antigenBiological: MART-1 antigenBiological: incomplete Freund's adjuvantBiological: sargramostimOther: laboratory biomarker analysis
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00089063
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Phase 2
Completed
- Conditions
- Recurrent Intraocular MelanomaRecurrent MelanomaStage IIIC MelanomaCiliary Body and Choroid Melanoma, Small SizeStage IIIA MelanomaStage IIIB Intraocular MelanomaExtraocular Extension MelanomaIris MelanomaCiliary Body and Choroid Melanoma, Medium/Large SizeStage IIIB Melanoma
- Interventions
- Biological: gp100 antigenBiological: tyrosinase peptideBiological: recombinant MAGE-3.1 antigenBiological: multi-epitope melanoma peptide vaccineBiological: incomplete Freund's adjuvantOther: laboratory biomarker analysis
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 42
- Registration Number
- NCT00085189
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
Phase 2
Completed
- Conditions
- Melanoma
- First Posted Date
- 2004-03-29
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT00080353
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
- First Posted Date
- 2003-04-28
- Last Posted Date
- 2012-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 138
- Registration Number
- NCT00059475
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
Phase 3
Completed
- Conditions
- Recurrent MelanomaStage IIIA Skin MelanomaStage IIIB Skin MelanomaStage IIIC Skin MelanomaStage IV Skin Melanoma
- Interventions
- Biological: AldesleukinOther: Quality-of-Life AssessmentBiological: gp100 AntigenOther: Questionnaire AdministrationOther: Laboratory Biomarker Analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 185
- Registration Number
- NCT00019682
- Locations
- 🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Phase 1
Completed
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia in RemissionChronic Phase Chronic Myelogenous LeukemiaPreviously Treated Myelodysplastic SyndromesRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in TransformationRelapsing Chronic Myelogenous Leukemia
- Interventions
- Biological: PR1 leukemia peptide vaccineBiological: sargramostimOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 69
- Registration Number
- NCT00004918
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Vaccination With Tetanus and KLH to Assess Immune Responses.
Terminated
- Conditions
- Cancer
- Interventions
- Biological: Biosyn KLHBiological: Intracel KLH VaccineBiological: Tetanus toxoid
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 112
- Registration Number
- NCT00000105
- Locations
- 🇺🇸
Division of Hematology, Oncology, and Transplantation 420 Delaware St., SE, Box 806 Mayo, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath